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Introduction 
Gene therapy constitutes a promising strategy for the 
treatment of acquired and inherited diseases but is largely 
dependent on the efficacy and tolerance of vectors.1-3 Due to their 
relative innocuity and their capacity to be readministered,4,5 the 
design of innovative non-viral delivery systems represents an 
active field of research. Although significant progresses have 
been performed – notably in vivo –,6 they led to lower transgene 
expression than viral carriers. Their optimization requires the 
understanding of the cellular steps encountered and the chemical 
adaptation of the carriers as well as their fine-tuned formulation 
combining different molecules with various properties. Indeed, 
non-viral transfection is actually a particularly delicate process 
involving several crucial steps: 1) the compaction of NA 
reducing its size and inducing a protection against DNase, 2) the 
internalization of the corresponding complexes usually by 
clathrin- and caveolae-mediated endocytosis,7 3) the endosomal 
escape of the NA and trafficking towards the nucleus, 4) the 
transcription and final production of the encoded protein. Among 
these steps, the escape of the NA from the endosomal 
compartment into the cytosol is a crucial stage to avoid 
lysosomal degradation. Different escape mechanisms from the 
endosome have been proposed for lipoplexes based upon the 
destabilization of the endosomal membrane,8-10 the exchange of 
cationic lipids with anionic phospholipids normally found on the 
cytoplasm-facing monolayer of the cell membrane,11 and 
endosomolysis caused by osmotic swelling12-14. Smart systems 
should provide versatile properties for protection and 
extracellular trafficking and sufficient instability promoting a 
rapid endosomal escape. The biological evolution of any 
endosome is known to induce a decrease of pH which can be 
used as a stimulus for pH-sensitive delivery systems.15,17 Our 
research group already described the use of stabilizing bipolar 
lipid for which the structure is based on archaeal lipids (Fig. 
1).18,19 We recently demonstrated the particular interest of this 
type of lipids for gene delivery. Tetraether archaeal lipids are 
known to span lipid membranes reducing the membrane 
dynamic, which results in a stabilization of the corresponding 
membranes. The monolayer-forming synthetic Tetraether 2 (Fig. 
1) was combined with a monocationic glycine betaine-derived 
lipid MM18 (Fig. 1) at various molar ratios and administered via 
systemic or local delivery routes.20 Following i.v. injection, 
MM18-based formulations demonstrated some high transfection 
efficiency in mice in vivo depending on the Tetraether 2 
proportion mixed. Noteworthy, a MM18/Tetraether 2 molar ratio 
of 10/1 was identified as the most efficient for in vivo gene 
transfection, especially into the lungs. Furthermore, when 
associated with MM18, this family of archaeal bipolar lipids 
showed more efficient in vitro gene transfection properties than 
common DOPE helper lipid.19 
With the aim of facilitating the endosomal escape step, we 
designed a novel tetraether helper lipid 3 including a pH-
cleavable moiety (Fig. 1). We based the pH-sensitivity function 
on orthoester moieties that cleave at pH around 5.21-23 Cleavage 
of an orthoester placed in the middle of the tetraether structure 
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leads to two monopolar diether-type lipids 9 (Fig.1) removing 
the stabilizing properties of the bipolar structure and therefore 
promoting a faster DNA release from the endosomal vesicles. 
Indeed, when combined with the cationic lipids, monopolar 
diethers are supposed to exhibit hexagonal phases,24 unlike 
tetraethers which facilitate the formation of lamellar phases.20 As 
a consequence, the change in lipid membrane organization 
provided by this chemical transformation of tetraethers into 
diethers, could promote the endosomal release. The present work 
describes the synthesis of this new diorthoester-based tetraether 3 
and the preliminary studies related to its efficiency to complex 
and to deliver plasmid DNA (pDNA) in in vitro assays when this 
novel helped lipid was combined with cationic lipid MM18.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and discussion 
The synthesis of the diorthoester-based tetraether 3 is based 
on the coupling of two equivalents of the functionalized alcohol 8 
with a diketene acetal 1022,23,25 under acidic conditions (Scheme 
1). The alcohol 8 was prepared in five steps from the glyceryl 
derivative 4 already described by our research group (in this case 
a racemic phytol was used instead of a 7R, 11R form).26 In more 
details, the deprotonation of 4 by action of NaH in THF and 
subsequent reaction with the bromo-Z-tetrapyranyl ether 527 led 
to the orthogonally protected diol 6 in a good yield (81%). 
Cleavage of the benzyloxy group by a palladocatalyzed 
hydrogenolysis afforded the alcohol 7 (82%), which was 
activated by mesylation (MsCl; Et3N). The substitution of the 
mesylate was carried out with sodium azide in the presence of 
TBABr leading to the introduction of the azide function on the 
glyceryl moiety. The methanolysis of the THPO ether under 
acidic conditions (PTSA, MeOH) finally conduced to the alcohol 
8 (98%), which was therefore ready for the coupling with the 
diketene acetal. At this stage of the synthesis, we also performed 
the reduction (PPh3 on resin, H2O) of the azide 8 leading to the 
corresponding amine 9, which served as a reference in the pH-
sensitivity and biological assays (Scheme 1). Indeed, monopolar 
amine 9 is the degradation product of tetraether 3 resulting from 
of the cleavage of the diorthoester function under acidic 
conditions. 
Alcohol 8 was engaged in the double coupling reaction with 
the diketene acetal 10 (Scheme 2). This step was carried out 
following procedures described previously.22,23,25  The PTSA 
catalyzed reaction cleanly produced at room temperature the 
diorthoester 11 (32%). To avoid extensive purification on silica 
gel that induced orthoester hydrolysis, we performed the last 
reduction step in the presence of a resin-supported 
triphenylphosphine that accomplished the Staudinger’s azide 
reduction in a quantitative yield affording the pH-sensitive 
tetraether 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As required for DNA complexation, we based our 
formulations on the cationic lipid MM18 (Fig.1). This original 
lipid from our research group has already demonstrated efficient 
gene transfer both in vitro18,28,29 and in vivo20. In particular, it 
revealed its higher transfection ability when mixed with helper 
lipids such a tetraether 2 for instance.18 As already shown, 
Tetraether co-lipids have to be incorporated in a small proportion 
in the liposomal vesicles in order to exhibit the best in vitro19 and 
in vivo20 transfection efficiencies. MM18 was thus combined 
with either Tetraether 3 as a novel helper lipid. The cationic 
lipid/colipid molar ratio was set at 10/1 (mol:mol) for 
formulation MM18/3, i.e. at the proportion that led to the best 
transfection efficiency with the non-cleavable Tetraether 2.20 
Hydration of lipid films constituted of a mixture of MM18/3 
10:1 permitted to prepare liposomal formulations which were 
then converted into lipoplexes with various charge ratios 
(DNA/cationic lipid ratios, i.e. +/- ratios) by mixing these lipid 
vesicles with DNA aqueous solutions. At low charge ratios 
(CR=1, excess of negative charges) corresponding to an excess of 
DNA, as well as at high charge ratios (CR=8), the lipoplexes 
were characterised by relatively small sizes (255 nm and 734 nm, 
respectively) with a polydispersity index (PdI) around 0.45, that 
were related to the repulsion of highly charged particles 
(negatively or positively). Indeed, these negative or positive 
particle surfaces were confirmed by the Zeta potential obtained in 
both cases (-33 mV and +58 mV, respectively). At CR=4, the 
relative neutralisation induced a slight aggregation leading to an 
increase of the particle sizes (2890 nm, PdI = 0.46). This 
phenomenon was even more pronounced in the case of quasi-
neutral Zeta potential (+5 mV, CR=2) which was characterised 
by high particle sizes (3450 nm, PdI = 0.82). This succession of 
zones (A–B–C) was already described for lipoplexes.30 
The MM18/3 liposomes were exposed to acidic conditions at 
37°C by addition of acetic or trifluoroacetic acid to evaluate their 
 
 
Figure 1. Molecular structure of natural (1), synthetic (2) and pH-
sensitive (3) tetraether lipids, diether lipid (9) and cationic lipid MM18. 
 
Scheme 1. Synthesis of the diorthoester-based tetraether 3. 
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pH-sensitivity. After fixing the pH to 3, 4, 5 or 6, the cleavage 
was followed by NMR analysis (see supporting information, 
Fig.S6). Between pH 6 and 5, the pH-sensitive lipid 3 was not 
cleaved even after 24h. Decreasing the pH to 4 led to a clear 
cleavage of lipid within the liposome, after 24h about 40% of 
lipid were cleaved. At pH=3, the lipid 3 was rapidly cleaved, 
more than 90% of cleavage was observed after 5h of exposure. 
pH-triggered cleavage in acidic media encouraged us to perform 
in vitro transfection evaluation of the corresponding lipoplexes. 
Indeed endosomal compartments reach mild acidic pH during its 
maturation.31  
MM18/3 lipoplexes were evaluated in transfection assays of 
four different cell lines: two human bronchial epithelial cells, 
wild type (16HBE 14o-) or cf -/- (CFBE), the alveolar type II 
epithelial cell line (A549), and the HEK 293 cells. The efficacy 
of both formulations was established for an increasing charge 
ratio from 1 to 8 in comparison with commercial cationic lipid 
Lipofectamine® (DOSPA:DOPE (3:1)) and according to 
routinely used and previously described procedures32 (Figure 2). 
The pH-cleavable formulation MM18/3 gave very interesting 
results for the four cell-types. In all cases the transfections 
efficiencies were higher than the lipofectamine® reference. 
Interestingly, the transfection was very efficient for the two cell-
types of interest (16HBE and CFBE). The optimal charge ratio 
was always 2 and a clear efficiency decrease was observed for 
CR=8 associated with an slight increase of the cytotoxicity (Fig. 
3). Further biological studies are now required to fully evaluate 
the impact of this tetraether lipid on transfection process, 
especially when higher amounts of this co-lipid are used in 
lipoplex formulations. The higher capacity of tetraether 3 to fully 
complex DNA and to exhibit high transfection levels compared 
with the reference commercial lipofection reagent 
Lipofectamine®, demonstrates a promising potential for its 
development as an helper lipid for gene delivery systems. 
 In parallel of the determination of the transfection efficiency, 
the evaluation of the cytotoxicity induced by the lipoplexes was 
performed using a chemiluminescent test (see supporting 
information). The results (Fig. 3) expressed in relative light units 
(RLU) showed low toxicities except for the higher charge ratio 
lipoplexes (CR=8).  
Conclusions 
In summary, non-viral gene delivery suffers from insufficient 
in vivo performances and needs new tools for a better delivery 
control. The present work described the synthesis of a new type 
of bipolar lipid that includes an orthoester function in the middle 
of the bridging chain that can be hydrolyzed upon exposure to 
acidic conditions. The key step of the synthetic scheme was 
based on the reaction of a diether lipid containing a free alcohol 
function at the terminal end of a lipophilic chain, with diketene 
acetal in the presence of an acidic catalyst. This straightforward 
approach proved to be an effective way of building symmetrical 
tetraether lipids containing a central pH-sensitive function. An 
original formulation based on this novel tetraether lipid promoted 
promising transfection efficiencies of pulmonary cell-types 
(16HBE and CFBE). A more complete biological study including 
in vivo evaluations will be carried out in due course to confirm 
the interest of such diorthoester-based bipolar lipid in gene 
delivery and to evaluate more deeply the role of the diorthoester 
moiety. In particular, the effect of this orthoester-containing 
bipolar lipid 3 on endosomal escape will be investigated in 
comparison with the corresponding tetraether lipid 2. Proton 
diffusion within the lipid membrane will be also evaluated 
through the use of the fluorescent pH indicator pyranine in order 
to  determine how the protons will get the hydrophobic interior to 
cleave the orthoester group. Furthermore, various lipid/co-lipid 
molar ratios will be tested with the aim of optimizing the 
influence of this novel tetraether by increasing its incorporation 
into formulations. 
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Figure 2. In vitro transfection efficacy of MM18/3 and Lipofectamine (LFM)-based lipoplexes with 16HBE 14o-, A549, CFBE 41o- and 
HEK293 cell lines. Cell lines were transfected with different formulations at various charge ratios. Untransfected cells and naked DNA were 
used as negative controls. Results are expressed as the Relative Light Units/mg of total proteins obtained with each formulation, reflecting their 
transfection abilities, as the mean  SD of 3 wells. 
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Supplementary data (all the data, NMR spectra for 
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Figure 3. In vitro cytotoxicity of MM18/3 and LFM-based lipoplexes on 16HBE 14o, A549, CFBE 41o- and HEK293 cell lines 3 h after addition 
of the different formulations onto the cells, the early cytotoxicity induced by the lipoplexes was performed by measuring the adenylate kinase 
released by the damaged cells, using a chemiluminescent test. The results were expressed in relative light units (RLU) and were conversely 
proportional to the number of living cells (untreated cells were used as reference). 
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Highlights: 
x  A novel archaeal tetraether with a pH-sensitive orthoester moiety was synthesized. 
x Lipid-DNA complexes based on cationic lipid and tetraether were formulated. 
x High in vitro transfection efficiencies and low toxicties were obtained. 
 
